Noncavitational nonporative ultrasound elicits marked in vivo augmentation of tumor drug delivery with perfluorocarbon nanoparticles

Steven L. Baldwin, Neelesh R. Soman, Gregory M. Lanza, Samuel A. Wickline

Research output: Contribution to journalConference article

Abstract

Background and Objective: Augmentation of local drug delivery from targeted nanoparticles (NP) with nondestructive, noncavitational clinical ultrasound (US) offers the potential to enhance therapeutic efficacy in diseases such as cancer while limiting adverse systemic side effects. This lab has demonstrated augmentation of drug delivery from avβ3-targeted perfluorocarbon NP and US in cancer cells in vitro (Crowder et al., 2005). The present study investigates the utility of conventional, clinical US for augmentation of drug delivery in vivo in a transgenic mouse cancer model (K14-HPV16) that develops squamous cell carcinomas.

Original languageEnglish
Article number4803564
Pages (from-to)566-569
Number of pages4
JournalProceedings - IEEE Ultrasonics Symposium
DOIs
StatePublished - Dec 1 2008
Event2008 IEEE International Ultrasonics Symposium, IUS 2008 - Beijing, China
Duration: Nov 2 2008Nov 5 2008

Keywords

  • Cancer
  • In vivo
  • Nanoparticles
  • Therapy
  • Ultrasound

Fingerprint Dive into the research topics of 'Noncavitational nonporative ultrasound elicits marked in vivo augmentation of tumor drug delivery with perfluorocarbon nanoparticles'. Together they form a unique fingerprint.

  • Cite this